DocumentRX-5216
Issued
Read2 min

FDA Moves to Withdraw Approval of FloLipid Liquid Simvastatin

The FDA proposes withdrawing FloLipid, Salerno Pharmaceuticals' liquid simvastatin, after repeated failures to file annual NDA reports. The company has until Dec. 18 to request a hearing.

TAG K-3717 · 427 words on the filing

FDA wants to remove cholesterol drug from market - Cardiovascular Business
FDA wants to remove cholesterol drug from market - Cardiovascular Businessanalogicus / pixabay

Summary of findings

  • FDA proposes withdrawing approval of FloLipid, a liquid simvastatin approved in 2016
  • Salerno Pharmaceuticals has until Dec. 18 to request a hearing
  • Full data submission deadline is Jan. 19, 2027
  • The action covers 20-mg and 40-mg doses of the drug
  • CDER director Michael Davis, MD, PhD, signed the notice

The FDA has proposed withdrawing approval of FloLipid, the liquid simvastatin marketed by Oklahoma-based Salerno Pharmaceuticals, after the company repeatedly failed to file required annual reports. If the withdrawal takes effect, the drug loses lawful interstate-commerce status across the United States.

The proposal covers the 20-mg and 40-mg doses of the formulation, which the FDA first approved in 2016. Salerno pitches FloLipid as the "first cholesterol medication in liquid form to be provided to U.S. patients," aimed at people who struggle to swallow pills. The product also ships without refrigeration requirements.

A liquid statin is a niche asset, not a blockbuster — but the compliance failure behind this action is the kind that turns an approved NDA into a liability.

Why is the FDA pulling the trigger now?

NDA holders must submit annual reports after approval. According to the FDA, Salerno failed to submit those reports on multiple occasions and then failed to respond when the agency came asking. That pattern, not any safety or efficacy finding, is what triggered the withdrawal proposal.

No clinical or manufacturing deficiency appears in the notice. The mechanism here is administrative: skipped reporting obligations, unanswered requests, and now the formal steps toward rescission.

What happens if Salerno stays silent?

The company has until Dec. 18 to request a hearing, per the Federal Register notice. It then has until Jan. 19, 2027, to submit all relevant data, including written comments.

Miss the hearing deadline and the consequences are automatic. The notice states that failure to request a hearing "constitutes a waiver of any contentions concerning the legal status of the drug products."

The language on what follows is unambiguous. "FDA will then withdraw approval of the NDA, and the drug products may not thereafter be lawfully introduced or delivered for introduction into interstate commerce," the proposal reads.

It adds: "Any new drug product introduced or delivered for introduction into interstate commerce without an approved NDA is subject to regulatory action at any time."

Michael Davis, MD, PhD, director of the FDA's Center for Drug Evaluation and Research, signed the notice.

What should portfolio holders take from this?

Approval is a standing obligation, not a finish line. Annual reporting lapses, left unanswered, can cost an NDA outright — regardless of the molecule's record.

Salerno still has its window. A hearing request by Dec. 18 and a full data submission by Jan. 19, 2027 would keep the process open. Whether the company engages at all, after years of non-response, is the open question the notice does not answer.

via FDA industry wire (Google News) (Source)

Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

10 articles

Linked filings

  1. P-6323
  2. E-4696
  3. E-9124
  4. K-1065
  5. P-6437

« Previous filingNext filing »